Stockscreener 앱 받기
72.81
0.15%
0.11
시간 외 거래:
72.81
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Holds Above $65 Support After Modest Pullback to $68.68Gap Up Stocks - vinanet.vn
TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Surges 4.6% to $67.76, Pressing Against ResistanceChandelier Stop - vinanet.vn
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle
The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Bank of America Corp DE - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus - Sahm
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104 - Moomoo
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results - MarketBeat
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid - insights.citeline.com
Tarsus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating - marketscreener.com
Tarsus joins Stargardt race to market with $800m Alkeus takeover - Yahoo Finance
Tarsus Pharmaceuticals acquires iRenix for $75 million upfront By Investing.com - Investing.com Nigeria
Tarsus to acquire Alkeus for $450M upfront plus milestones By Investing.com - Investing.com South Africa
Tarsus to Acquire Alkeus in $450 Million Deal, Reports Strong Quarter and Half - VisionMonday.com
Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals - Latham & Watkins LLP
Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push - Law360
Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside - TradingView
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highli - GuruFocus
Tarsus to purchase Alkeus Pharmaceuticals - glance.eyesoneyecare.com
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive
Tarsus Pharmaceuticals, Inc. entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. for approximately $800 million. - marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... - Yahoo Finance
Tarsus Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TARS) 2026-08-06 - Seeking Alpha
Tarsus Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Tarsus Pharmaceuticals Raises 2026 XDEMVY Net Pdt Sales Guidance to $685M-$705M >TARS - Moomoo
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Tarsus Pharmaceuticals (TARS) Positioned for Growth After Q2 - GuruFocus
Tarsus Pharmaceuticals, Inc. - Reuters
Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million By Investing.com - Investing.com Nigeria
TARS Looks 71.0% Undervalued on GF Value™ but Faces Price-to-Sal - GuruFocus
Tarsus Pharmaceuticals raises $125 million in PIPE financing - Investing.com
Tarsus bets $450M on Alkeus’ Stargardt drug - Endpoints News
Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million - Investing.com
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlook - TradingView
Tarsus Pharmaceuticals (TARS) boosts H1 2026 revenue and turns operating cash flow positive - Stock Titan
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing - The Manila Times
Tarsus Pharmaceuticals raises $125 million in PIPE financing By Investing.com - Investing.com Nigeria
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth - GlobeNewswire
Press Release: Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position - Moomoo
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position - The Manila Times
Tarsus Pharmaceuticals to report Q2 2026 financ... - Pluang
Tarsus sets 5 a.m. PT webcast for Aug. 6 financial update - Stock Titan
0.00%
3.22%
자본화:
|
볼륨(24시간):